OBJECTIVE: To evaluate the accuracy of a peptide, corresponding to the variant surface glycoprotein (VSG) LiTat 1.5 amino acid (AA) sequence 268-281 and identified through alignment of monoclonal antibody selected mimotopes, for diagnosis of Trypanosoma brucei gambiense sleeping sickness. METHODS: A synthetic biotinylated peptide (peptide 1.5/268-281), native VSG LiTat 1.3 and VSG LiTat 1.5 were tested in an indirect ELISA with 102 sera from patients with HAT and 102 endemic HAT-negative controls. RESULTS: The area under the curve (AUC) of peptide 1.5/268-281 was 0.954 (95% confidence interval 0.918-0.980), indicating diagnostic potential. The areas under the curve of VSG LiTat 1.3 and LiTat 1.5 were 1.000 (0.982-1.000) and 0.997 (0.973-1.000), respectively, and significantly higher than the AUC of peptide 1.5/268-281. On a model of VSG LiTat 1.5, peptide 1.5/268-281 was mapped near the top of the VSG. CONCLUSIONS: A biotinylated peptide corresponding to AA 268-281 of VSG LiTat 1.5 may replace the native VSG in serodiagnostic tests, but the diagnostic accuracy is lower than for the full-length native VSG LiTat 1.3 and VSG LiTat 1.5.
OBJECTIVE: To evaluate the accuracy of a peptide, corresponding to the variant surface glycoprotein (VSG) LiTat 1.5 amino acid (AA) sequence 268-281 and identified through alignment of monoclonal antibody selected mimotopes, for diagnosis of Trypanosoma brucei gambiense sleeping sickness. METHODS: A synthetic biotinylated peptide (peptide 1.5/268-281), native VSG LiTat 1.3 and VSG LiTat 1.5 were tested in an indirect ELISA with 102 sera from patients with HAT and 102 endemic HAT-negative controls. RESULTS: The area under the curve (AUC) of peptide 1.5/268-281 was 0.954 (95% confidence interval 0.918-0.980), indicating diagnostic potential. The areas under the curve of VSG LiTat 1.3 and LiTat 1.5 were 1.000 (0.982-1.000) and 0.997 (0.973-1.000), respectively, and significantly higher than the AUC of peptide 1.5/268-281. On a model of VSG LiTat 1.5, peptide 1.5/268-281 was mapped near the top of the VSG. CONCLUSIONS: A biotinylated peptide corresponding to AA 268-281 of VSG LiTat 1.5 may replace the native VSG in serodiagnostic tests, but the diagnostic accuracy is lower than for the full-length native VSG LiTat 1.3 and VSG LiTat 1.5.
Authors: V Lejon; V Jamonneau; P Solano; P Atchade; D Mumba; N Nkoy; N Bébronne; T Kibonja; F Balharbi; A Wierckx; M Boelaert; P Büscher Journal: Trop Med Int Health Date: 2006-05 Impact factor: 2.622
Authors: Dieudonné Mumba Ngoyi; Veerle Lejon; Pati Pyana; Marleen Boelaert; Médard Ilunga; Joris Menten; Jean Pierre Mulunda; Simon Van Nieuwenhove; Jean Jacques Muyembe Tamfum; Philippe Büscher Journal: J Infect Dis Date: 2010-02-01 Impact factor: 5.226
Authors: O Clyde Hutchinson; Kim Picozzi; Nicola G Jones; Helen Mott; Reuben Sharma; Susan C Welburn; Mark Carrington Journal: BMC Genomics Date: 2007-07-13 Impact factor: 3.969
Authors: Rocío Camargo; Adriana Izquier; Graciela L Uzcanga; Trina Perrone; Alvaro Acosta-Serrano; Liomary Carrasquel; Laura P Arias; José L Escalona; Vanessa Cardozo; José Bubis Journal: Vet Parasitol Date: 2014-11-13 Impact factor: 2.738
Authors: Sylvain Biéler; Harald Waltenberger; Michael P Barrett; Richard McCulloch; Jeremy C Mottram; Mark Carrington; Wilhelm Schwaeble; James McKerrow; Margaret A Phillips; Paul A Michels; Philippe Büscher; Jean-Charles Sanchez; Richard Bishop; Derrick R Robinson; James Bangs; Michael Ferguson; Barbara Nerima; Audrey Albertini; Gerd Michel; Magdalena Radwandska; Joseph Mathu Ndung'u Journal: PLoS One Date: 2016-12-09 Impact factor: 3.240
Authors: Crispin Lumbala; Paul R Bessell; Pascal Lutumba; Sylvain Baloji; Sylvain Biéler; Joseph M Ndung'u Journal: PLoS One Date: 2017-07-03 Impact factor: 3.240